Don't Just Read the News, Understand It.
Published loading...Updated

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Summary by Watauga Democrat
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets

25 Articles

All
Left
6
Center
5
Right
3
Chatham Star TribuneChatham Star Tribune
+20 Reposted by 20 other sources
Center

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets

Joincare Group to Lead Clinical Development and Commercialization of BRII-693 in Greater China Brii Biopharma Retains Commercialization Rights Outside of Greater China to Address Global Antimicrobial Resistance Threats and Continues to Focus on Other Priority Pipeline Assets BEIJING, China and DURHAM, N.C., July 4, 2025 /PRNewswire/ -- Brii Biopharma Inc. ("Bi Biopharma" or the "Company", stock code: 2137.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 43% of the sources lean Left
43% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Friday, July 4, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.